73 related articles for article (PubMed ID: 8657419)
1. [Efficacy of combined oral hormone replacement therapy in postmenopausal symptoms].
Szántó F; Hörömpöli C
Orv Hetil; 1996 May; 137(20):1079-81. PubMed ID: 8657419
[TBL] [Abstract][Full Text] [Related]
2. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN
Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449
[TBL] [Abstract][Full Text] [Related]
3. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women.
Josse RG
CMAJ; 1996 Oct; 155(7):929-34. PubMed ID: 8837542
[TBL] [Abstract][Full Text] [Related]
4. Lower doses of oral estrogen and progestogens as treatment for postmenopausal women.
Archer DF
Semin Reprod Med; 2005 May; 23(2):188-95. PubMed ID: 15852205
[TBL] [Abstract][Full Text] [Related]
5. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
6. Comparative cardiovascular effects of different progestins in menopause.
Rosano GM; Fini M
Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
[TBL] [Abstract][Full Text] [Related]
7. Postmenopausal hormone therapy: cardiovascular risks.
Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
[TBL] [Abstract][Full Text] [Related]
8. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
Dew JE; Wren BG; Eden JA
Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
[TBL] [Abstract][Full Text] [Related]
10. Effect of initial gestagen treatment on bleeding patterns in postmenopausal women receiving continuous combined hormone replacement therapy.
Büyük E; Durmuşoğlu F; Dökmeci C
Menopause; 1999; 6(2):156-60. PubMed ID: 10374223
[TBL] [Abstract][Full Text] [Related]
11. Is combined estrogen/progestogen hormone therapy worth the risk?
Sturdee DW; MacLennan AH
Climacteric; 2003 Sep; 6(3):177-9. PubMed ID: 14567764
[No Abstract] [Full Text] [Related]
12. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.
Davies GC; Huster WJ; Shen W; Mitlak B; Plouffe L; Shah A; Cohen FJ
Menopause; 1999; 6(3):188-95. PubMed ID: 10486787
[TBL] [Abstract][Full Text] [Related]
13. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study.
Chompootaweep S; Nunthapisud P; Trivijitsilp P; Sentrakul P; Dusitsin N
Clin Pharmacol Ther; 1998 Aug; 64(2):204-10. PubMed ID: 9728901
[TBL] [Abstract][Full Text] [Related]
14. [The role of vaginal smears in the follow-up od menopausal symptoms].
Szántó F
Orv Hetil; 1998 Mar; 139(12):693-5. PubMed ID: 9555166
[TBL] [Abstract][Full Text] [Related]
15. [Risks and benefits of postmenopausal hormone replacement therapy].
Szántó F
Orv Hetil; 1998 Nov; 139(44):2639-42. PubMed ID: 9842237
[TBL] [Abstract][Full Text] [Related]
16. Hormone replacement therapy and breast density changes.
Harvey J; Scheurer C; Kawakami FT; Quebe-Fehling E; de Palacios PI; Ragavan VV
Climacteric; 2005 Jun; 8(2):185-92. PubMed ID: 16096175
[TBL] [Abstract][Full Text] [Related]
17. Treatment options and menopause regimens.
Farrell E
Aust Fam Physician; 1992 Mar; 21(3):240-6. PubMed ID: 1605762
[TBL] [Abstract][Full Text] [Related]
18. [Authors' experience with transvaginal administration of progestagens].
Cataldi U; Tridente V; Pazienza S; Brizzi C; Serrao L; Proia L; Quattrini MJ
Clin Ter; 1997 Apr; 148(4):165-72. PubMed ID: 9377851
[TBL] [Abstract][Full Text] [Related]
19. Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance.
Erenus M; Karakoç B; Gürler A
Climacteric; 2001 Sep; 4(3):228-34. PubMed ID: 11588947
[TBL] [Abstract][Full Text] [Related]
20. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
